Fragile X syndrome: an important preventable cause of mental handicap
Males outnumber females by three to two among the mentally handicapped'-mainly because about a quarter of X linked conditions are associated with mental handicap.2 One fifth of boys with intelligence quotients between 35 and 50 are retarded because of a gene on the X chromosome3-as are about one in 2600 males outside institutions. 4 Perhaps a third of those who are mentally handicapped because of a gene on the X chromosome have the semidoniinant fragile X syndrome. 5 In 1943 Martin and Bell described a family with 11 severely retarded males, and the bigenerational pedigree showed sex linked inheritance.6 (The fragile X syndrome is also called the Martin-Bell syndrome.) Almost four decades later Richards showed that five of seven surviving members of the family described by Martin and Bell had a secondary constriction at position 27, near the end of the long arm of the X chromosome.7 -This followed the development of "banding" techniques, and Lubs had described four males in three generations with such a fragile site.a
The phenotype is fairly distinctive. Large testes should raise the suspicion of the fragile X syndrome, and the patient usually has a high forehead, a big jaw, long "bat" ears, and a "dysplastic" asymmetrical facies. Large hands and blue eyes may also be found, but apart from the eye and ear signs these features are seldom seen in prepubertal boys.
Two of the original Martin-Bell family had "pronounced psychotic traits," and Lejeune has reported that "psychotic like" symptoms in seven of eight patients with the fragile X syndrome were much improved by folic acid or 5-formyltetrahydrofolate.9 Those with the syndrome may have autistic features (with or without hyperkinesis),"'020 although some have argued that the two conditions are not associated.2' I have noted a tendency to unprovoked violent outbursts and have described the condition in fraternal twins with antisocial personalities.22 Most of those affected are severely mentally subnormal, although atypical variants may have normal intelligence-thus transmission of the fragile site by normal "carrier males" has been reported.2324 Most carrier females have normal intelligence, but Turner et al found that about one third of heterozygotes were handicapped in some sense."
A recent Australian study argued for a widescale preventive screening programme,4 although the case for folate -treatment is unproved.26 This would be extremely cost effective, but, as British cytogenetic facilities are already overloaded, we should concentrate on screening high risk groups: families with more than one retarded male; children born to "borderline" mothers; and those who are retarded and who also have large testes, autism, or the Prader-Willi syndrome. Some of those in special hospitals might also be included.
The male fetuses of carriers can be aborted, and given a 50% chance of having an affected child most women would probably opt for termination. Antenatal screening is not sufficiently reliable to allow routine testing, but the techniques are being refined.27-30
Considerations other than technological advances and providing extra laboratory and genetic counselling resources must, however, be addressed before mass screening programmes can be introduced in Britain. The care of the handicapped has been demedicalised and socialised, and biological research is now anathema to some carers. I know of one county social services department that refused to allow screening of the relatives of affected clients. An extensive public health education programme-as for rubella or Down's syndrome-may be required to render the soil more fertile. That screening is possible and worth while in Britain has, however, been shown by a study in Coventry, where among 50000 schoolchildren one in 1360 boys and one in 2073 girls had the fragile X syndrome. 3' Screening is thus to be encouraged, but those undertaking it must remember the harm that may be done to families by saying where the defect originated. And what is to be done with the female fetuses who have the syndrome, most of whom will be phenotypically normal?
H G KINNELL When should patients be referred for liver transplantation?
Liver transplantation is being used increasingly for patients with liver disease. In Europe in 1982 fewer than 100 transplants were performed, whereas in 1986 the number was about 450, 130 of them in Britain. The results are such that even two years ago Starzl, the pioneer of the procedure, was quoting actuarial five year survival rates of over 60%.' But, though the indications are now well recognised,23 the problem remains as to when liver transplantation should be done. Three years ago a National Institutes of Health consensus conference concluded that "an ideally timed transplantation procedure would be in a late enough phase of the disease to offer the patient no opportunity for spontaneous stabilisation or recovery, but in an early enough phase to give the surgical procedure a fair chance of success."4 Liver transplantation is usually performed when the prognosis, with conventional treatment, is one year of life or when the symptoms are intolerable. Nevertheless, inherent in the consensus conference's statement is the unproved assumption that both the prognostic factors for survival and the factors that adversely affect surgery can be identified for the individual patient. What guidance, therefore, can we give the physician on when adults should be referred to a transplant centre?
The absolute contraindications to transplantation are few and easy to identify: advanced cardiac and pulmonary disease, active biliary sepsis, continued excess alcohol consumption, and, for almost all centres, extrahepatic spread of primary liver tumour or the presence of metastases in the liver.5 Less clear cut is age since many centres have done successful transplants in patients of over 60. Previous upper abdominal surgery is often considered a relative contraindication; although, especially when portal hypertension is present, adhesions do add considerably to the difficulties, no study has shown that previous laparotomy adversely affects survival.67 The presence of a blocked portal vein is no longer considered to be a contraindication to grafting. In patients with replicating hepatitis B virus the virus will probably infect the graft,8 9 but even if this occurs the quality of life after surgery may be excellent for some years. (The advent of newer techniques to prevent reinfection or treat chronic infection may make this less of a problem.) Evidence that the non-A non-B viruses affect the grafted liver is conflicting. 10.12 Those causes of fulminant hepatic failure associated with a poor prognosis (such as non-A non-B viral hepatitis, fulminant Budd-Chiari syndrome, or drug sensitivity) are now further indications for transplantation. Potential candidates must be transferred to the transplant unit early: not only is there a short time span between the certainty that the prognosis is poor without transplantation and the onset of irreversible neurological damage, but also transferring a patient with encephalopathy carries increased risk ofcerebral oedema and irreversible cerebral damage. '3 Patients with hepatic malignancy should be referred for transplantation as soon as the presence of a non-resectable primary liver tumour confined to the liver is established. (It is appreciated that preoperative imaging will miss a proportion of extrahepatic metastases anrd that recurrence of the disease remains a considerable problem.'4) Diagnostic biopsy of the tumour carries the potential risk of dissemination, but the need to confirm that the tumour is both malignant and primary usually outweighs these risks.
In patients with chronic parenchymal disease assessment of prognosis remains a problem. Prognostic models have been developed for both primary biliary cirrhosis'5 and chronic active hepatitis,'6 but, though these have been validated for populations, they are of less value for the individual. As the disease progresses nutrition becomes increasingly poor and poses an added risk.'7 Given that rapid correction carries the risk of myelinolysis, hyponatraemia adds another risk to the procedure.'8 A raised serum creatinine concentration has been suggested as a risk factor,6 but whether preoperative correction by, for example, dialysis improves the risk is to be shown.
Even if risk factors could be readily estimated, however, ethical considerations demaind that patients with a limited prognosis without transplantation should not be denied operation merely because they are bad risks. As soon as a liver transplant becomes a possibility, therefore, they should be referred to a transplant centre. Not only can the patients be assessed by the physicians, surgeons, anaesthetists, nurses, and the other supporting staffconcerned but they can also assess the liver transplant centre and discuss the procedure and its long term sequels with patients who have undergone it. If the transplant team consider that a patient is referred too early, then he or she should be followed up by the referring physician, possibly with occasional reassessment at the transplant centre. Optimum management of the potential candidates demands close liaison between the local hospital and the transplant unit. Confidence must exist between both parties: confidence by the referring physician that his patient will not be precipitated too early into hazardous surgery and confidence by the transplant team that it will not be called on to perform "miracles" in moribund patients.
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